Approved & therapeutic
Cerebrolysin
Brain-Derived Neurotrophic Peptide Mix
A mixture of neuropeptides derived from pig brain tissue. Widely used outside the US for stroke recovery, traumatic brain injury, and cognitive decline.
Also known as: FPF-1070
- Status
- Cerebrolysin is approved in at least one country outside the U.S. but not approved by the FDA.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~30-60 minutes (effects persist)
- How it's taken
- IV infusion or intramuscular injection
- Mechanism
- Cognitive / mood
- Pathways
- Neurotrophic
How Cerebrolysin works
Contains a mix of small neurotrophic peptides that cross the blood-brain barrier. These mimic the activity of natural nerve growth factors (NGF and BDNF), supporting neuron survival, growth, and new connection formation.
What research has looked at
- Neuroprotective after brain injury
- May improve recovery after stroke
- Supports memory and cognitive function
- Used in Alzheimer's research
- Promotes neuroplasticity
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Dizziness
- Headache
- Agitation
- Injection site reactions
- GI discomfort
- Must be given IV or IM (not subcutaneous)
Sources
- PubMed research on cerebrolysin stroke dementia clinical · NIH · National Library of Medicine
- Active clinical trials for cerebrolysin · U.S. National Library of Medicine
- DrugBank record for cerebrolysin · DrugBank
Track Cerebrolysin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Cerebrolysin FAQ
What is Cerebrolysin?
A mixture of neuropeptides derived from pig brain tissue. Widely used outside the US for stroke recovery, traumatic brain injury, and cognitive decline.
How does Cerebrolysin work?
Contains a mix of small neurotrophic peptides that cross the blood-brain barrier. These mimic the activity of natural nerve growth factors (NGF and BDNF), supporting neuron survival, growth, and new connection formation.
Is Cerebrolysin FDA approved?
No. Cerebrolysin is approved in at least one country outside the U.S. but not approved by the FDA. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Cerebrolysin?
Reported half-life: ~30-60 minutes (effects persist).
How is Cerebrolysin taken?
IV infusion or intramuscular injection.
What side effects have been reported with Cerebrolysin?
Reported in the sources: Dizziness; Headache; Agitation; Injection site reactions; GI discomfort; Must be given IV or IM (not subcutaneous).
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.